Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
Fierce Pharma4d
With blood and growth disorder bids panning out, Novo Nordisk plots path to rare disease leadership: exec
Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...
Seeking Alpha19d
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk is doing exceptionally well in the ... which is a long-acting growth hormone. Thanks to less frequent injections and the fact that it is not inferior to Norditropin, Sogroya is ...
pharmaphorum4d
Novo puts $285m into monthly GLP-1 based on Ascendis tech
Novo Nordisk has ... version of parathyroid hormone (PTH), which is for the treatment of hypoparathyroidism in adults, and Skytrofa (lonapegsomatropin), a long-acting growth hormone for ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Seeking Alpha1mon
Novo Nordisk: 2024 Earnings Review
Novo Nordisk's 2024 earnings exceeded estimates ... a once-weekly treatment for growth hormone deficiency. As for blood disorders, sales also grew by 3%, boosted by increased sales of products ...
Investing21d
Novo Nordisk's SWOT analysis: stock poised for growth amid challenges
The company's GLP-1 receptor agonist products, Ozempic (semaglutide) for type 2 diabetes and Wegovy (semaglutide) for weight management, have been driving significant growth and market share gains.